Identification of CD8 +CD25 +Foxp 3+ suppressive T cells in colorectal cancer tissue

Gut

Volumn 58, Issue 4, 2009, Pages 520-529

  Chaput, N ^a,b   Louafi, S ^a   Bardier, A ^c   Charlotte, F ^c   Vaillant, J C ^a   FMenegaux ^a   Rosenzwajg, M ^a   Lemoine, F ^a   Klatzmann, D ^a   Taieb, J ^a,d  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c Service d'Anatomopathologie   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER TISSUE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL INFILTRATION; CELL ISOLATION; CELL POPULATION; CELL PROLIFERATION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; IN VITRO SELECTION; INVASIVE CARCINOMA; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TUMOR IMMUNITY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYTOKINES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNE TOLERANCE; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM STAGING; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 63849224217     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2008.158824     Document Type: Article

References (49)

1. Ferlay J, Bray F, Pisani P, et al. Cancer incidence, mortality and prevalence worldwide. GLOBOCAN 2002; IARC CancerBase No.5, Version 2.0. Lyon: IARC Press (2004).
2. Skibber J, Minsky B, Hoff P. Cancer of the colon. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer principles and practice of oncology, Philadelphia: Lippincott Williams & Wilkins, 2001: 1217.
3. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353:2654-66.
4. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4.
5. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
6. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nature Rev 2003;3:253-7.
7. Clarke SL, Betts GJ, Plant A, et al. CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS ONE 2006;1:e129.
8. Ling KL, Pratap SE, Bates GJ, et al. Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun 2007;7:7.
9. Loddenkemper C, Schernus M, Noutsias M, et al. In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer. J Transl Med 2006;4:52.
10. Tang XL, Smith TR, Kumar V. Specific control of immunity by regulatory CD8 T cells. Cell Mol Immunol 2005;2:11-9.
11. Cosmi L, Liotta F, Lazzeri E, et al. Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes. Blood 2003;102:4107-14.
12. Rifa'i M, Kawamoto Y, Nakashima I, et al. Essential roles of CD8+CD122+ regulatory T cells in the maintenance of T cell homeostasis. J Exp Med 2004;200:1123-34.
13. Xystrakis E, Dejean AS, Bernard I, et al. Identification of a novel natural regulatory CD8 T-cell subset and analysis of its mechanism of regulation. Blood 2004;104:3294-301.
14. Dhodapkar MV, Steinman RM. Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans. Blood 2002;100:174-7.
15. Gilliet M, Liu YJ. Generation of human CD8 regulatory T cells by CD40 ligand- activated plasmacytoid dendritic cells. J Exp Med 2002;195:695-704.
16. Kumar V, Sercarz E. An integrative model of regulation centered on recognition of TCR peptide/MHC complexes. Immunol Rev 2001;182:113-21.
17. Kiniwa Y, Miyahara Y, Wang HY, et al. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res 2007;13:6947-58.
18. Sather BD, Treuting P, Perdue N, et al. Altering the distribution of Foxp3(+) regulatory T cells results in tissue-specific inflammatory disease. J Exp Med 2007;204:1335-17.
19. Beyer M, Kochanek M, Giese T, et al. In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood 2006;107:3940-9.
20. Curti A, Pandolfi S, Valzasina B, et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ regulatory T cells. Blood 2007;109:2871-7.
21. Liu VC, Wong LY, Jang T, et al. Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ regulatory T cells: role of tumor-derived TGF- beta. J Immunol 2007;178:2883-92.
22. Valzasina B, Piconese S, Guiducci C, et al. Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. Cancer Res 2006;66:4488-95.
23. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
24. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13.
25. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800.
26. Krambeck AE, Thompson RH, Dong H, et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A 2006;103:10391- 6.
27. Johnson BF, Clay TM, Hobeika AC, at al. Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Expert Opin Biol Thar 2007;7:449-60.
28. Lyakh LA, Sanford M, Chekol S, at al. TGF-beta and vitamin D3 utilize distinct pathways to suppress IL-12 production and modulate rapid differentiation of human monocytes into CD83+ dendritic cells. J Immunol 2005;174:2061-70.
29. Sharma S, Yang SC, Zhu L, at al. Tumor cyclooxygenase-2/ prostaglandin E2- dependent promotion of FOXP3 expression and CD4+ CD25+ regulatory T cell activities in lung cancer. Cancer Ras 2005;65:5211-20.
30. Ghiringhelli F, Puig PE, Roux S, at al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Mad 2005;202:919- 29.
31. Filaci G, Fenoglio D, Fravega M, at al. CD8+ CD28- Regulatory T lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J Immunol 2007;179:4323-34.
32. Filaci G, Suciu-Foca N. CD8+ T suppressor cells are back to the game: are they players in autoimmunity? Autoimmun Rav 2002;1:279-83.
33. Cosmi L, Liotta F, Angeli R, at al. Th2 cells are less susceptible than Th1 cells to the suppressive activity of CD25+ regulatory thymocytes because of their responsiveness to different cytokines. Blood 2004;103:3117-21.
34. Sugita S, Futagami Y, Horie S, at al. Transforming growth factor beta-producing Foxp3(+)CD8(+)CD25(+) T cells induced by iris pigment epithelial cells display regulatory phenotype and acquire regulatory functions. Exp Eya Ras 2007;85:626-36.
35. Le Gouvello S, Bastuji-Garin S, Aloulou N, at al. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut 2008;57:772-9.
36. Wagsater D, Lofgren S, Hugander A, Dimberg J. Expression of interleukin-17 in human colorectal cancer. Anticancar Ras 2006; 26(6B):4213-6.
37. Wei S, Kryczek I, Zou L, at al. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancar Ras 2005;65:5020-6.
38. Yang ZZ, Novak AJ, Ziesmer SC, at al. CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells. Blood 2007;110:2537-44.
39. Yamazaki S, Bonito AJ, Spisek R, at al. Dendritic cells are specialized accessory cells along with TGF- for the differentiation of Foxp3+ CD4+ regulatory T cells from peripheral Foxp3 precursors. Blood 2007;110:4293-302.
40. Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Natura Rav 2007;7:817-23.
41. Watanabe N, Wang YH, Lee HK, at al. Hassall's corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus. Natura 2005;436:1181-5.
42. Bettelli E, Carrier Y, Gao W, at al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Natura 2006;441:235-8.
43. Liu SJ, Tsai JP, Shen CR, at al. Induction of a distinct CD8 Tnc17 subset by transforming growth factor-beta and interleukin-6. J Lauk Biol 2007;82:354-60.
44. Ahmadzadeh M, Antony PA, Rosenberg SA. IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells. J Immunothar 2007;30:294-302.
45. Brozek W, Bises G, Girsch T, at al. Differentiation- dependent expression and mitogenic action of interleukin-6 in human colon carcinoma cells: relevance for tumour progression. Eur J Cancar 2005;41:2347-54.
46. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancar 2005;41:2502-12.
47. Hsu CP, Chung YC. Influence of interleukin-6 on the invasiveness of human colorectal carcinoma. Anticancar Ras 2006;26:4607-14.
48. Naugler WE, Sakurai T, Kim S, at al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Scianca 2007;317:121-4.
49. Schafer ZT, Brugge JS. IL-6 involvement in epithelial cancers. J Clin Invast 2007;117:3660-3.